BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 36720446)

  • 1. Targeted silencing of the MCL-1 gene using multi-layered dendrimer-based nanoconstructs achieves efficient tumor regression in xenografted mice models.
    Tambe P; Salve R; Choudhary P; Kumar P; Jadhav S; Paknikar KM; Gajbhiye V
    Int J Pharm; 2023 Mar; 634():122659. PubMed ID: 36720446
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Triptorelin Tethered Multifunctional PAMAM-Histidine-PEG Nanoconstructs Enable Specific Targeting and Efficient Gene Silencing in LHRH Overexpressing Cancer Cells.
    Tambe P; Kumar P; Karpe YA; Paknikar KM; Gajbhiye V
    ACS Appl Mater Interfaces; 2017 Oct; 9(41):35562-35573. PubMed ID: 28949503
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Down-regulation of Mcl-1 by small interference RNA induces apoptosis and sensitizes HL-60 leukemia cells to etoposide.
    Karami H; Baradaran B; Esfehani A; Sakhinia M; Sakhinia E
    Asian Pac J Cancer Prev; 2014; 15(2):629-35. PubMed ID: 24568469
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Folic acid-decorated polyamidoamine dendrimer exhibits high tumor uptake and sustained highly localized retention in solid tumors: Its utility for local siRNA delivery.
    Xu L; Yeudall WA; Yang H
    Acta Biomater; 2017 Jul; 57():251-261. PubMed ID: 28438704
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficient delivery of sticky siRNA and potent gene silencing in a prostate cancer model using a generation 5 triethanolamine-core PAMAM dendrimer.
    Liu X; Liu C; Laurini E; Posocco P; Pricl S; Qu F; Rocchi P; Peng L
    Mol Pharm; 2012 Mar; 9(3):470-81. PubMed ID: 22208617
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ionizing radiation sensitizes breast cancer cells to Bcl-2 inhibitor, ABT-737, through regulating Mcl-1.
    Wu H; Schiff DS; Lin Y; Neboori HJ; Goyal S; Feng Z; Haffty BG
    Radiat Res; 2014 Dec; 182(6):618-25. PubMed ID: 25409124
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Enhancement of chemosensitivity by simultaneously silencing of Mcl-1 and Survivin genes using small interfering RNA in human myelomonocytic leukaemia.
    Jafarlou M; Shanehbandi D; Dehghan P; Mansoori B; Othman F; Baradaran B
    Artif Cells Nanomed Biotechnol; 2018 Dec; 46(8):1792-1798. PubMed ID: 29113504
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lipidoid nanoparticle mediated silencing of Mcl-1 induces apoptosis in mantle cell lymphoma.
    Knapp CM; He J; Lister J; Whitehead KA
    Exp Biol Med (Maywood); 2016 May; 241(9):1007-13. PubMed ID: 27022142
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Co-Delivery of Gemcitabine and Mcl-1 SiRNA via Cationic Liposome-Based System Enhances the Efficacy of Chemotherapy in Pancreatic Cancer.
    Wang Y; Gao F; Jiang X; Zhao X; Wang Y; Kuai Q; Nie G; He M; Pan Y; Shi W; Ren S; Yu Q
    J Biomed Nanotechnol; 2019 May; 15(5):966-978. PubMed ID: 30890228
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Triple negative breast cancers express receptors for LHRH and are potential therapeutic targets for cytotoxic LHRH-analogs, AEZS 108 and AEZS 125.
    Seitz S; Buchholz S; Schally AV; Weber F; Klinkhammer-Schalke M; Inwald EC; Perez R; Rick FG; Szalontay L; Hohla F; Segerer S; Kwok CW; Ortmann O; Engel JB
    BMC Cancer; 2014 Nov; 14():847. PubMed ID: 25410881
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inhibition of human experimental prostate cancers by a targeted cytotoxic luteinizing hormone-releasing hormone analog AN-207.
    Stangelberger A; Schally AV; Nagy A; Szepeshazi K; Kanashiro CA; Halmos G
    Prostate; 2006 Feb; 66(2):200-10. PubMed ID: 16173040
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mcl-1 as a potential therapeutic target for human hepatocelluar carcinoma.
    Yu Q; Liu ZY; Chen Q; Lin JS
    J Huazhong Univ Sci Technolog Med Sci; 2016 Aug; 36(4):494-500. PubMed ID: 27465322
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Surface-engineered targeted PPI dendrimer for efficient intracellular and intratumoral siRNA delivery.
    Taratula O; Garbuzenko OB; Kirkpatrick P; Pandya I; Savla R; Pozharov VP; He H; Minko T
    J Control Release; 2009 Dec; 140(3):284-93. PubMed ID: 19567257
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Silencing of myeloid cell leukemia-1 by small interfering RNA improves chemosensitivity to etoposide in u-937 leukemic cells.
    Jafarlou M; Baradaran B; Shanehbandi D; Saedi TA; Jafarlou V; Karimi P; Othman F
    J Biol Regul Homeost Agents; 2016; 30(1):55-65. PubMed ID: 27049076
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Polymeric delivery of siRNA for dual silencing of Mcl-1 and P-glycoprotein and apoptosis induction in drug-resistant breast cancer cells.
    Aliabadi HM; Mahdipoor P; Uludağ H
    Cancer Gene Ther; 2013 Mar; 20(3):169-77. PubMed ID: 23449477
    [TBL] [Abstract][Full Text] [Related]  

  • 16. AEZS-108 : a targeted cytotoxic analog of LHRH for the treatment of cancers positive for LHRH receptors.
    Engel J; Emons G; Pinski J; Schally AV
    Expert Opin Investig Drugs; 2012 Jun; 21(6):891-9. PubMed ID: 22577891
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Improved delivery of Mcl-1 and survivin siRNA combination in breast cancer cells with additive siRNA complexes.
    Santadkha T; Skolpap W; K C R; Ansari A; Kucharski C; Atz Dick T; Uludağ H
    Invest New Drugs; 2022 Oct; 40(5):962-976. PubMed ID: 35834040
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Anticancer siRNA cocktails as a novel tool to treat cancer cells. Part (B). Efficiency of pharmacological action.
    Dzmitruk V; Szulc A; Shcharbin D; Janaszewska A; Shcharbina N; Lazniewska J; Novopashina D; Buyanova M; Ionov M; Klajnert-Maculewicz B; Gómez-Ramirez R; Mignani S; Majoral JP; Muñoz-Fernández MA; Bryszewska M
    Int J Pharm; 2015 May; 485(1-2):288-94. PubMed ID: 25796120
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Inhibitory effect of silencing STAT3 gene with short hairpin RNA mediated by polyamidoamine dendrimers on growth of prostate cancer].
    Zhao WM; Xiu YC; Xu Y; Wang YM; Cheng ZK; Yu Q; Kong DL
    Zhonghua Zhong Liu Za Zhi; 2007 Aug; 29(8):575-9. PubMed ID: 18210874
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Myeloid cell leukemia-1 is an important apoptotic survival factor in triple-negative breast cancer.
    Goodwin CM; Rossanese OW; Olejniczak ET; Fesik SW
    Cell Death Differ; 2015 Dec; 22(12):2098-106. PubMed ID: 26045046
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.